Patents by Inventor Jeremy P. W. Heaton
Jeremy P. W. Heaton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8168232Abstract: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.Type: GrantFiled: February 25, 2010Date of Patent: May 1, 2012Assignee: Queen's University at KingstonInventors: Charles H. Graham, Lynne-Marie Postovit, Michael A. Adams, Jeremy P. W. Heaton
-
Publication number: 20110028543Abstract: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.Type: ApplicationFiled: February 25, 2010Publication date: February 3, 2011Applicant: Queens University at KingstonInventors: Charles H. Graham, Lynne-Marie Postovit, Michael A. Adams, Jeremy P. W. Heaton
-
Patent number: 7678391Abstract: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.Type: GrantFiled: March 6, 2003Date of Patent: March 16, 2010Inventors: Charles H. Graham, Lynn-Marie Postovit, Michael A. Adams, Jeremy P. W. Heaton
-
Patent number: 7393825Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to 1/20) of those known to induce vasodilation in “normal” circulations.Type: GrantFiled: June 11, 2003Date of Patent: July 1, 2008Assignee: Strakan International LimitedInventors: Jeremy P. W. Heaton, Michael A. Adams, James D. Banting
-
Patent number: 6946484Abstract: Methods and formulations for inhibiting and preventing a malignant cell phenotype by administering to cells a low dose of a nitric oxide mimetic are provided.Type: GrantFiled: April 26, 2001Date of Patent: September 20, 2005Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Charles H. Graham, Jeremy P. W. Heaton, Lynne-Marie Postovit
-
Publication number: 20040234619Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: ApplicationFiled: June 15, 2004Publication date: November 25, 2004Applicant: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Jeremy P.W. Heaton
-
Patent number: 6787553Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: GrantFiled: July 9, 2002Date of Patent: September 7, 2004Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Jeremy P. W. Heaton
-
Publication number: 20040166176Abstract: In the field of treatment of erectile dysfunction there is disclosed a novel therapy in which the actions of an agent or agents, produce a combination of effects to induce effective erection (and avoid priapism) while reducing or entirely avoiding pain. The method taught combines a first action of an agent which is to antagonize a drug-induced pain stimulus within nociceptive nerves of penile tissue with a second action of either the same agent or of a second agent, which enhances, synergistically, smooth muscle relaxation. The synergism allows for at least an equivalent effect of smooth muscle relaxation to be obtained at significantly lower doses of a smooth muscle relaxing agent such as PGE1 which in standard therapy is also in 40-45% of cases pain-inducing at doses which achieve effective erection.Type: ApplicationFiled: February 23, 2004Publication date: August 26, 2004Applicant: Cellegy Pharmaceuticals Inc.Inventors: Michael A. Adams, Jeremy P.W. Heaton, Donald H. Maurice
-
Publication number: 20040138291Abstract: This invention relates to a method of normalizing sexual response in a subject, comprising administering to a subject in need thereof an anti-hypertensive therapy and a centrally-acting dopaminergic agonist. The subject may be a human male or female. In a preferred embodiment, the anti-hypertensive therapy is an ACE inhibitor such as enalapril, and the centrally-acting dopaminergic agonist is apomorphine or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: October 10, 2003Publication date: July 15, 2004Inventors: Michael A. Adams, Jeremy P.W. Heaton, Taben M. Hale, Rochard K.S. Beharry
-
Patent number: 6756407Abstract: The present invention provide a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation or diminished clitoral orgasm, or of combating vaginal pain by stimulating peripheral pelvic nerve release of nitric oxide (NO). The method comprises administering to a female in need of such treatment a therapeutically effective amount of a compound which acts on a mid-brain pathway to increase blood flow to the ilio-hypogastric-pudendal artery bed and stimulate the release of nitric oxide (NO) from peripheral NANC nerve cells. The preferred compound for the method of this invention is apomorphine or one of its pharmaceutically acceptable salts, esters, or pro-drugs.Type: GrantFiled: April 22, 2002Date of Patent: June 29, 2004Assignee: Queen's University at KingstonInventors: Jeremy P. W. Heaton, Michael A. Adams
-
Patent number: 6747063Abstract: In the field of treatment of erectile dysfunction there is disclosed a novel therapy in which the actions of an agent or agents, produce a combination of effects to induce effective erection (and avoid priapism) while reducing or entirely avoiding pain. The method taught combines a first action of an agent which is to antagonize a drug-induced pain stimulus within nociceptive nerves of penile tissue with a second action of either the same agent or of a second agent, which enhances, synergistically, smooth muscle relaxation. The synergism allows for at least an equivalent effect of smooth muscle relaxation to be obtained at significantly lower doses of a smooth muscle relaxing agent such as PGE1 which in standard therapy is also in 40-45% of cases pain-inducing at doses which achieve effective erection.Type: GrantFiled: October 23, 1998Date of Patent: June 8, 2004Assignee: Cellegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Jeremy P. W. Heaton, Donald H. Maurice
-
Publication number: 20040092493Abstract: Impotence can be ameliorated without substantial undesirable side effects by nasal administration of apomorphine, optionally with an antiemetic agent present in an amount sufficient to substantially reduce nausea symptoms that may be associated with the use of apomorphine.Type: ApplicationFiled: May 19, 2003Publication date: May 13, 2004Inventors: Ragab El-Rashidy, Jeremy P.W. Heaton, Alvaro Morales, Michael A. Adams
-
Publication number: 20040063719Abstract: The present invention provides a method for a more efficacious treatment of a vascular condition through the administration of a therapeutically effective amount of a combination of an anti-pressor agent, an endothelin antagonist, and a sex hormone for repetitive cycles of on/off-treatment. In one embodiment, the invention provides a method for the prevention of tolerance induced by an anti-pressor agent via the inclusion of an endothelin antagonist in a combination therapy approach to remodel vascular structure and treat vascular conditions associated with a male or female sexual dysfunction, atherosclerosis, renal failure, hypertension, congestive heart failure, diabetic nephropathy, and diabetic neuropathy.Type: ApplicationFiled: May 2, 2003Publication date: April 1, 2004Applicants: Queen's University at Kingston, Callegy Pharmaceuticals, Inc.Inventors: Michael A. Adams, Taben M. Hale, Jeremy P.W. Heaton
-
Publication number: 20030215528Abstract: The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.Type: ApplicationFiled: March 6, 2003Publication date: November 20, 2003Applicant: Queens University at KingstonInventors: Charles H. Graham, Lynne-Marie Postovit, Michael A. Adams, Jeremy P.W. Heaton
-
Publication number: 20030195140Abstract: Methods and compositions for improving sleep in individuals with sleep disorders or other conditions which interfere with normal sleep via administration of a NO-mimetic are provided.Type: ApplicationFiled: March 11, 2003Publication date: October 16, 2003Applicant: Vaxis Therapeutics Corporation, now CellegyCanada, Inc.Inventors: C. Bruce Ackman, Michael A. Adams, Jeremy P.W. Heaton, Jodan D. Ratz
-
Patent number: 6610652Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations.Type: GrantFiled: March 8, 2002Date of Patent: August 26, 2003Assignee: Queen's University at KingstonInventors: Michael A. Adams, Jeremy P. W. Heaton, James D. Banting
-
Patent number: 6586391Abstract: The mechanism of hypertension following acute NO synthase blockage is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a ‘normal’ physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.Type: GrantFiled: July 18, 2000Date of Patent: July 1, 2003Assignee: Queen's University at KingstonInventors: James D. Banting, Jeremy P. W. Heaton, Michael A. Adams
-
Patent number: 6586478Abstract: Methods and compositions for improving sleep in individuals with sleep disorders or other conditions which interfere with normal sleep via administration of a NO-mimetic are provided.Type: GrantFiled: February 22, 2001Date of Patent: July 1, 2003Assignee: Cellegy CanadaInventors: C. Bruce Ackman, Michael A. Adams, Jeremy P. W. Heaton, Jodan D. Ratz
-
Publication number: 20030092725Abstract: The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The method is applicable not only to adjusting or normalizing the timing of sexual response in humans, but in the breeding of valuable commercial animals such as horses, cattle, sheep, swine and the like and domesticated pets such as dogs and cats.Type: ApplicationFiled: May 20, 2002Publication date: May 15, 2003Inventors: Jeremy P.W. Heaton, Michael A. Adams
-
Publication number: 20030008020Abstract: The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudendal arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, &agr;1-adrenergic receptor antagonists, &bgr;-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors.Type: ApplicationFiled: July 9, 2002Publication date: January 9, 2003Applicant: Queen's University of KingstonInventors: Michael A. Adams, Jeremy P.W. Heaton